Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 5/20 | 0.37 |
| ▸ | ACACA | Q13085 | 4/20 | 0.37 |
| ▸ | GYS1 | P13807 | 11/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15919379 | 0.97 | ACACB (0.36) | ACACBACACAGYS1MEN1KMT2A | |
| SCHEMBL15919290 | 0.95 | ACACB (0.38) | ACACBACACAGYS1MEN1KMT2A | |
| SCHEMBL15919289 | 0.93 | ACACB (0.41) | ACACBACACAKCNQ1TRPV1 | |
| SCHEMBL17323683 | 0.93 | ACACB (0.37) | ACACBACACAGYS1MEN1KMT2A | |
| SCHEMBL15919377 | 0.92 | ACACB (0.37) | ACACBACACAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL15919486 | 0.90 | KMT2A (0.36) | ACACBACACAGYS1MEN1KMT2A | |
| SCHEMBL15919288 | 0.89 | GYS1 (0.35) | GYS1MEN1KMT2ASMN1; SMN2NPSR1 | |
| SCHEMBL15919284 | 0.88 | ACACB (0.41) | ACACBACACAKMT2AKCNQ1 | |
| SCHEMBL17323689 | 0.88 | ACACB (0.38) | ACACBACACAKMT2AKCNQ1 | |
| SCHEMBL15919415 | 0.88 | GYS1 (0.35) | GYS1MEN1KMT2ASMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663488-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663488-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2015-12-10 | — | — | US | disclosed |
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2015-12-10 | — | — | US | disclosed |
| WO-2014117090-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2014-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | ACACB 1141/4885ACACA 1262/4885GYS1 2885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.